Atossa Genetics Novel Test Could Generate Nice Profits [View article]
Are the ATOS tests approved by the FDA? If the tests are as credible as stated, why have they not replaced the mammagram? Are the ATOS tests expensive?
Cel-Sci: Immunotherapy Opens New Door To Investors [View article]
I spend much time in Israel on business. TEVA is considered a very smart!!! and important company. I believe that if TEVA was behind CVM it was a very good buy at 29 cents. I just bought more at 23 for the same reason and as a result of management's inside buying. However, insiders bought at higher amounts too and nothing happened. Does the CEO have a hidden agenda for us to buy at this low level?
Neuralstem (CUR -13.7%) continues to give back it's big gains from yesterday, declining again today after pricing a secondary offering for 7M shares at $1.00 per share, a 27% discount to its previous close. The company intends to use the funds for clinical trials, R&D as well as other general purposes. [View news story]
I assume we must wait just a bit longer for a run - up. Much like PSTI. What is good is that someone out there recognizes the potential.
Pluristem Therapeutics (PSTI +4.2%) enjoys continued upward momentum after Thursday's news that it received permission from India's health ministry to proceed with a Phase II clinical trial for the treatment of Buerger's disease. The trial could be followed by a larger multi-national Phase III. Shares popped 10% yesterday on the announcement. [View news story]
I am an aggressive, middle age investor. I live in both Nashville and Israel.
PSTI is an exciting company with huge possibilities. I totally agree with Scott Matusow that PSTI and ATRS are retirement quality stocks.
Atossa Genetics Novel Test Could Generate Nice Profits [View article]
Apricus Biosciences: A Transformative Year Ahead [View article]
After APRI dropped below $3, I began to consider buying it. Did you ever buy a long position in the stock?
Cel-Sci: Immunotherapy Opens New Door To Investors [View article]
Is Opko Still A Buy As Frost Continues To Purchase Shares? [View article]
Cel-Sci: Immunotherapy Opens New Door To Investors [View article]
It is now the end of March. Are you still long CVM? I am and I need some hand holding to feel better.
Neuralstem (CUR -13.7%) continues to give back it's big gains from yesterday, declining again today after pricing a secondary offering for 7M shares at $1.00 per share, a 27% discount to its previous close. The company intends to use the funds for clinical trials, R&D as well as other general purposes. [View news story]
7 Low-Debt Small Cap Healthcare Stocks Positioned For Growth [View article]
Pluristem Therapeutics (PSTI +4.2%) enjoys continued upward momentum after Thursday's news that it received permission from India's health ministry to proceed with a Phase II clinical trial for the treatment of Buerger's disease. The trial could be followed by a larger multi-national Phase III. Shares popped 10% yesterday on the announcement. [View news story]
PSTI is an exciting company with huge possibilities. I totally agree with Scott Matusow that PSTI and ATRS are retirement quality stocks.